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Abstract
Introduction: The primary objective of the LanroNET study was to evaluate the resource utilisation and cost of symptomatic treatment 
of patients with neuroendocrine tumours (NET) using lanreotide autogel 120 mg.
Material and methods: LanroNET was a multicentre, non-interventional, prospective study conducted at 12 clinical centres in Poland. Eligible 
patients were adults with symptomatic NET treated with lanreotide autogel 120 mg at least three months before enrolment. During 24-months of 
observation of real clinical practice, data on medical resource utilisation and the therapy course of patients with symptomatic NET were collected. 
Results: Fifty-four patients with symptomatic NET were enrolled. The median time of lanreotide exposure was 1.7 years (range: 0.0–2.2). 
Thirty-three patients completed the study; the most frequent known cause of discontinuation (8/16) was disease progression. The mean 
cost of consumed resources without the cost of pharmacotherapy was estimated at PLN 26,307/EUR 6030.35 per year. During the study, 
the mean (SD) interval between injections was 31.7 days (6.7). At the end of observation — after 24 months of follow-up, seven patients 
were on a 42-day regimen. The average real-world cost of lanreotide autogel 120 mg was PLN 4216.30/EUR 966.49 per patient/28 days from 
the public payer and patient perspective and was lower by PLN 554.14/EUR 127.02 than the cost for the standard 28-day dosing interval.
Conclusions: LanroNET is the first two-year observational study of patients with symptomatic NET evaluating the cost of every-day 
clinical practice and lanreotide autogel treatment in Poland. (Endokrynol Pol 2018; 69 (5): 567–572)
Key words: symptomatic neuroendocrine tumours, lanreotide, cost analysis
Streszczenie
Wstęp: Celem badania LanroNET była ocena wykorzystania zasobów medycznych oraz kosztów objawowego leczenia polskich chorych 
na nowotwory neuroendokrynne z zastosowaniem lanreotydu autogel 120 mg. 
Materiał i metody: LanroNET to wieloośrodkowe, nieinterwencyjne, obserwacyjne, prospektywne badanie przeprowadzone w 12 ośrod-
kach w Polsce. W badaniu uczestniczyli dorośli chorzy na wydzielające nowotwory neuroendokrynne leczeni lanreotydem autogel 120 mg 
od przynajmniej 3 miesięcy przed włączeniem do badania. Podczas 24-miesięcznej obserwacji rzeczywistej praktyki klinicznej zbierano 
dane dotyczące wykorzystania zasobów medycznych oraz przebiegu terapii chorych z wydzielającymi nowotworami neuroendokrynnymi. 
Wyniki: W badaniu uczestniczyło 54 chorych na wydzielające nowotwory neuroendokrynne. Przeciętny czas stosowania lanreotydu 
wynosił 1,7 roku (zakres 0,0–2,2 lata). Badanie ukończyło 33 pacjentów, najczęstszą przyczyną przedwczesnego zakończenia leczenia 
(8/16) była progresja choroby. Całkowity średni koszt wykorzystanych zasobów bez kosztów farmakoterapii oszacowano na 26 307 zł/EUR 
6.030,35 na pacjenta/rok. W czasie badania średni odstęp między wstrzyknięciami lanreotydu wynosił 31,7 dni (6,7). Pod koniec obserwacji, 
po 24 miesiącach od follow-up, 7 pacjentów stosowało 42-dniowe odstępy między dawkami. Średni rzeczywisty koszt lanreotydu autogel 
120 mg wyniósł 4216,30 zł/966,49 EUR na pacjenta/28 dni we wspólnej perspektywie płatnika i pacjenta i był niższy o 554,16 zł/127,02 EUR 
niż koszt stosowania standardowych 28-dniowych odstępów między dawkami.
Wnioski: Badanie LanroNET jest pierwszym w Polsce obserwacyjnym dwuletnim badaniem chorych na czynne hormonalnie nowotwo-
ry neuroendokrynne żołądkowo-jelitowo-trzustkowe oceniającym koszty codziennej praktyki klinicznej i koszty leczenia lanreotydem 
autogel. (Endokrynol Pol 2018; 69 (5): 567–572)
Słowa kluczowe: objawowe nowotwory neuroendokrynne, lanreotyd, analiza kosztów
Maria Jessa-Jabłońska, Ipsen Poland, Medical Affairs, 29th Jana Pawła II St., 00–867 Warsaw, Poland; tel.: +48 22 653 68 00, e-mail: maria.
jessa-jablonska@ipsen.com
568
PR
A
C
E 
O
RY
G
IN
A
LN
E
Lanreotide costs in NET symptom therapy Ewa Orlewska et al.
during the follow-up were withdrawn from the study, 
with exception of less than eight weeks’ break due to 
radioisotope therapy. 
A sample size of 50 patients was estimated based on 
Polish epidemiological data, assuming that there were 
approximately 350 patients with symptomatic NET, 
and 18% of them were treated with lanreotide autogel 
120 mg. It was considered that around 80% of eligible 
patients will consent to participate in the study. All con-
secutive patients were invited to participate in the study 
during inpatient and outpatient visits at the study sites. 
Study visits, treatment monitoring procedures, and 
dose adjustments were made according to routine clini-
cal practice at participating sites, up to 24 months after 
enrolment. The enrolment visit procedures included 
a review of relevant demographic characteristics, medi-
cal and treatment history, NET diagnostic characterisa-
tion and/or prior medication (therapies/surgeries for 
NET), NET symptoms, lanreotide autogel dose admin-
istered, aspects of administration (site of administration 
and person administering the drug), and injection 
intervals. The follow-up visit procedures included 
a review of current treatment details and changes in 
the treatment scheme and administration, and NET 
symptoms. Diagnostic procedures were recorded only 
if performed as part of a routine assessment during 
a visit. Adverse events (AEs) reporting followed regula-
tions related to spontaneous reporting. Investigators 
were asked to report only related AEs. Study comple-
tion was defined as 24 months of follow-up completed, 
or the patients attended a visit that the investigator 
labelled as the last visit.
The primary objective of the LanroNET study was 
to assess the resource utilisation and cost of lanreotide 
autogel 120 mg when administrated as part of a routine 
treatment of NET symptoms.
All statistical analyses were descriptive. Six study 
sites provided unit costs; the mean of these costs was 
used in the base case scenario for each resource type 
(without weighting). In addition, sensitivity analyses 
were performed in which extreme scenarios were 
considered: minimum scenario (lowest unit cost) and 
maximum scenario (highest unit cost). The mean costs, 
and lowest and highest unit costs are presented in Sup-
plementary Table S1. 
Cost evaluation for lanreotide autogel 120 mg was 
performed from the perspective of the public payer in 
2016 and patients, based on reimbursement status and 
retail price of Somatuline® Autogel from 1st June 2016, 
which was 4770.46 PLN/1093.52 EUR [10]. Costs in EUR 
were calculated based on the 2016 average PLN/EUR rate: 
4.3625 PLN = 1 EUR [11]. Resource utilisation costs were 
assessed using a micro-costing approach. In the sensitivity 
analysis, the extreme scenarios were analysed: minimum 
Introduction
Neuroendocrine tumour (NET) pharmacotherapy ob-
jectives are symptom control and the control of tumour 
progression. The long-acting analogues of somatostatin 
(lanreotide and octreotide) are used for the control of 
symptoms of hormonally active NET and tumour pro-
gression in advanced inoperable disease. The position 
in the therapy schemes of these two synthetic soma-
tostatin analogues (SSA) is well established in current 
guidelines and recommendations [1–7]. According to 
the Polish Network of Neuroendocrine Tumours, SSAs 
are now indicated as a gold standard of symptomatic 
treatment of functional gastroenteropancreatic NETs 
(GEP-NETs) and recommended as the first-line therapy 
in midgut and pancreatic NET. Octreotide is recom-
mended for the control of midgut NET G1 with low 
hepatic tumour load, while lanreotide is recommended 
in midgut and pancreatic NET G1 and G2 (Ki-67 index 
up to 10%) irrespective of hepatic tumour load [3–7]. 
The resource utilisation and cost of the treatment 
with lanreotide autogel 120 mg of symptomatic NETs in 
routine clinical practice were followed over 24 months. 
It provides evidence on the use of a drug in a real-life 
setting, which is a growing need for Polish payers and 
can serve to address multiple post-approval objectives. 
In contrast to some other countries, extended-dosing 
intervals (EDIs) with lanreotide autogel 120 mg (> 28 
days) are licensed in Poland in symptomatic NET, which 
may have an impact on resource utilisation. This study, 
therefore, followed the real-world practice of lanreotide 
autogel 120 mg utilisation in patients with symptomatic 
NETs between mid-2012 and mid-2015. In April 2015 
lanreotide autogel 120 mg was registered in Poland for 
the treatment of grade 1 and a subset of grade 2 (Ki67 
index up to 10%) GEP-NET of the midgut, pancreatic, 
or unknown origin where hindgut sites of origin have 
been excluded, in adult patients with unresectable lo-
cally advanced or metastatic disease. This registration 
was based on the CLARINET study results [8]. 
Material and methods
The LanroNET study methodology was described 
previously [9]. LanroNET was a multicentre, non-
interventional, longitudinal study conducted in Poland. 
Fourteen sites that treated eligible patients were con-
tacted to propose participation, and two sites declined 
to participate. Eligible patients were adults with symp-
tomatic NETs treated with lanreotide autogel 120 mg 
for at least three months before inclusion. The decision 
to initiate treatment with lanreotide autogel 120 mg 
was independent of the decision to enrol patients into 
the study. Patients terminating lanreotide treatment 
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scenario (with minimum values for unit cost) and maxi-
mum scenario (with maximum values for unit cost).
Results
Patients
Fifty-four patients with a mean age of 60.5 years, bala-
nced between male and female (Table I) received lan-
reotide autogel 120 mg treatment for a mean (± SD) of 
1.4 ± 0.7 years and median (range) 1.7 (0.0–2.2) years. 
Figure 1. Study design (A) and patient disposition (B); *either 
24 months of follow-up completed (n = 26) or the investigator 
labelled visit as last (n = 7), #disease progression as recorded by 
the investigator (no further definition available)
Rycina 1. Projekt badania (A) i przepływ pacjentów (B); 
*zakończone 24 miesiące obserwacji (n = 26) lub wizyta określona 
przez badacza jako ostatnia (n = 7), #progresja choroby oceniona 
przez badacza (brak dostępnej definicji)
A
B
months treatment before enrollment
Inclusion visit
24-months visit 
or final visit in eCRF
Total screened (n = 57)
Enrolled (n = 54)
Completed* (n = 33)
Excluded (n = 3)
 Reason for exclusion not know
Withdrawn (n = 21)
#
 disease progression  (n = 8)
 other (n = 8)
 missing (n = 5)
Follow-up visits as per routine clinical practice
Table I. Baseline characteristics and demographics of patients 
enrolled in the LanroNET study
Tabela I. Charakterystyka wyjściowa i dane demograficzne 
pacjentów włączonych do badania LanroNET
Characteristic Population (N = 54)
Age, mean ± SD, years 60.5 ± 0.7
Weight, mean ± SD, kg 73.6 ± 14.8
Male gender, n (%) 27 (50.0)
Performance status (ECOG–WHO), n (%)
0
1
2
3
4
NA = 2
19 (36.5)
22 (42.3)
9 (17.3)
2 (3.8)
0 (0.0)
Origin of NET, n (%)
Gastrointestinal tract
Bronchopulmonary system
Pancreas
Colon/rectum
Unknown
27 (50.0)
3 (5.6)
8 (14.8)
7 (13.0)
9 (16.
Proliferation grading
G1
G2
G3
NA = 10
30 (68.2)
10 (22.7)
4 (9.1)
Ki-67 index categories
0–2%
> 2–20%
> 20%
NA = 19
27 (77.1)
6 (17.1)
2 (5.7)
Metastases present, n (%)
At multiple sites
54 (100)
45 (83.3)
Previous treatment for NET*, n (%)
Surgery
Somatostatin analogues
Chemotherapy
PRRT
46 (85.2)
43 (79.6)
6 (11.1)
27 (50.0)
Medical history#, n (%)
Hypertension
Diabetes
Cholelithiasis
34 (63.0)
13 (24.1)
4 (7.4)
ECOG–WHO Eastern Cooperative Oncology Group–World Health Organisation, 
NA — not available (number of patients with data missing), PRRT — Peptide 
Receptor Radionuclide Therapy, SD — standard deviation; *previous treatments 
include monotherapy and combination therapy; #patients could report more 
than one medical history event
Over 60% of the patients (n = 33, 61.1%) completed 
the study: n = 26 (48.1%) with 24 months of follow-
up; n = 3 (5.6%) with last visit at 18 months; and n = 4 
(7.4%) with last visit at 21 months. The most frequent 
recorded cause of discontinuation (8/21) was disease 
progression (Figure 1). Most patients scored 0 or 1 on 
the ECOG scale (Eastern Cooperative Oncology Group). 
Half of the patients had primary tumours located in the 
gastrointestinal tract. All enrolled patients presented 
metastases. At baseline, over two-thirds of patients 
(n = 30, 68.2%) presented with a well-differentiated 
tumour (G1) according to the WHO 2010 Classification 
[12]. Thirty-six (66.7%) patients reported at least one 
medical history at baseline (Table I).
Prior to study enrolment, 46 (85.2%) patients had 
undergone surgery. On average, the last surgery had 
occurred 4.6 ± 4.0 years before inclusion in the study. 
Forty-three (79.6%) patients had been treated with SSAs 
prior to the three-month pre-inclusion phase. Moreover, 
27 patients (50.0%) had been previously treated with 
Peptide Receptor Radionuclide Therapy (PRRT).
NET therapy during 24-month therapy with  
lanreotide autogel 120 mg
At baseline, 13% of patients did not report NET symp-
toms that could have resolved during the pre-inclusion 
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phase. The most frequent symptoms at baseline were 
abdominal pain, diarrhoea (n = 30 each, 55.6%), flushing 
(n = 27, 50%), and fatigue (n = 19, 35.2%). The proportion 
of patients affected by NET symptoms decreased over 
the course of the study. After 24-months 9/25 patients 
(36%) reported “none or improved” symptom(s). After 
24-months of observation, diarrhoea was reported in 
7/25 patients (28%), abdominal pain was reported in 4/25 
patients (16%), and flushing was reported in 8/25 (32%) 
patients with available data at baseline and at 24 months. 
At baseline, most patients with available data (n = 
27, 77.1%) showed a Ki-67 index between 0% and 2%, 
which corresponds to a low proliferation index of the 
primary tumour (Table I). The mean concentration of 
chromogranin A (CgA) at baseline was 1140.98 ng/ml 
(indicative reference value: < 98 ng/ml [13]). The mean 
level of urinary 5-hydroxyindoleacetic acid (5-HIAA) 
was at baseline 37.51 mg/24 h (indicative reference 
value: 2–7 mg/24 h [14]).
Three patients experienced serious adverse events 
during the study. One patient experienced cholecysto-
lithiasis and one patient experienced cholelithiasis. Both 
events were considered serious and related to lanreo-
tide. One patient died 24 days after the last lanreotide 
administration due to cardiopulmonary failure in the 
context of advanced NET disease.
Resource utilisation
The resource utilisation analysed during lanreotide 
autogel 120 mg treatment included hospitalisations, 
out-patient consultations, pathological marker tests, 
and diagnostic procedures (Table II). Forty patients 
(74.1%) were hospitalised at least once. These patients 
were hospitalised on average (SD) 7.0 (± 4.4) times per 
year. Moreover, each patient also consulted doctors 
a mean of 10.8 times per year (N = 50). In patients who 
underwent at least one diagnostic imaging procedure 
during the study (n = 15), the mean (SD) number of 
procedures per year was 0.95 (± 0.46) (Table II). The 
most frequently used marker was CgA, with an average 
of 3.5 tests per year for the 42 patients who underwent 
at least one test. For 5-HIAA, the mean was 1.6 tests per 
year for the 31 patients with a minimum of one such test 
during the observation. Testing for insulin, calcitonin, 
gastrin, or serum neuron-specific enolase was done in 
4, 3, 2, and 1 patient(s), respectively, during the study. 
The total mean cost of consumed resources per pa-
tient per year was estimated at PLN 26,307/EUR 6030. 
Cost of hospitalisations represented 92.04% of the total 
cost, out-patient consultations contributed 6.21%, and 
pathological marker tests and diagnostic procedures ac-
counted for 1.3% and 0.44%, respectively. The cost distri-
bution in the minimum and the maximum scenarios was 
similar to that seen in the base case analysis (Table II).
Lanreotide autogel 120 mg treatment and cost
The mean (SD) and median duration of lanreotide 
autogel 120 mg exposure was 1.4 ± 0.72 and 1.7 years 
(range: 0.0–2.2), respectively (four patients remained in 
the study for only one day). At baseline nine patients 
(19.7%) were treated with lanreotide autogel 120 mg 
injection received at an EDI (> 4 weeks) (Table III). 
In the enrolled population, the mean number of days 
between injections was 31.7 (n = 50). Dosing regimen 
Table II. Annualised resource utilisation during lanreotide autogel 120 mg treatment
Tabela II. Roczne wykorzystanie zasobów podczas leczenia lanreotide autogel 120 mg
Resource type Patients using 
resource ≥ 1#,  
n (%)
Annualised 
resource use
Mean ± SD/ 
/year
Annualised cost — best case 
scenario
Average cost/patient/year
[PLN/EUR] (% of total cost)
Annualised cost — 
minimum scenario
Average cost/
patient/year
[PLN/EUR]
Annualised cost — 
maximum scenario
Average cost/patient/ 
/year
[PLN/EUR]
Hospitalisations 40 (74.1) 6.98 ± 4.35* 24,214.00/5550.49 (92.04) 11,603.00/2659.71 99,190.00/22,736.96
Outpatient consultations 50 (92.6) 10.78 ± 2.28 1633.00/374.32 (6.21) 764.60/175.26 5,390.00/1235.53
Diagnostic procedures## 15 (27.7) 0.95 ± 0.46 116.00/26.59 (0.44) 13.92/3.19 1,421.00/325.73
Pathological markers
CgA
5-HIAA
Other###
42 (77.8)
31 (57.4)
1–14
3.49 ± 2.42
1.56 ± 1.36
344.00/78.85 (1.30)
140.00/32.09
80.00/18.33
180.00/41.26
132.00/30.25
12.55/2.87
553.60/126.90
411.00/94.21
78.38/17.96
Total cost of resources consumed per patient per year (with 
exception of pharmaceuticals)
26,307.00/6030.26/(100) 12,552.00/2877.25 106,555.00/24,425.21
#the number of patients using the resource at least once during the study. All prospectively recorded data was missing for 4 patients of 54 observed. These 4 patients 
stayed only one day in the study; ##diagnostic procedures include imaging of thorax, abdomen, and pelvis; ###other pathological marker tests used were for cortisol 
(n = 14), ACTH (n = 13), 5-HT (n = 8), insulin (n = 4), calcitonin (n = 3), gastrin (n = 2), and serum neuron-specific enolase (n = 1); *one patient of 40 hospitalised 
patients stayed in the study for only one day and was not included in the analysis; PLN Polish zloty; EUR Euro
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was extended (at HCP discretion) in four patients dur-
ing first nine months after enrolment into the study. The 
proportion of patients treated with EDI increased during 
the study, and at the end of the 24-month observation 
27% of patients were on a six-week dosing regimen 
(Table III). Two patients were on eight-week dosing 
frequency during the study. Five patients withdrew 
from the study after switching from lanreotide autogel 
120 mg to another treatment: octreotide LAR (n = 2), 
PRRT (n = 2), and brachytherapy (n = 1). On average 
(SD), lanreotide autogel 120 mg was injected 10.5 (± 2.6) 
times year. Drug administrations were performed in an 
outpatient setting (n = 450, 53.7%) and in a hospital (n = 
387, 46.2%). All but one injection were made by nurses.
The mean cost of lanreotide autogel 120 mg per pa-
tient for a 28-day period (irrespective of regimen) was 
PLN 4212.5/EUR 965.61 and PLN 3.80/EUR 0.87 from 
the public payer and patient perspective, respectively 
(total PLN 4216.30/EUR 966.48; Table III). 
Discussion
In the study population, GEP-NETs were the most com-
mon (n = 42, 77.8%). At inclusion into the study patients 
were almost fully ambulatory as shown by their ECOG 
performance status. Every second patient underwent 
prior PRRT; however, it should be noted that PRRT proce-
dures were historically developed and frequently used in 
Poland [15]. Over 60% of the enrolled patients completed 
the study. The most frequent reason for discontinuation of 
the treatment was disease progression, although informa-
tion on how investigators defined progressive disease was 
not documented. According to recent guidelines, disease 
progression is not an indication to stop symptomatic 
treatment [3]. The percentage of patients negatively af-
fected by NETs symptoms decreased to 36% during the 
two-year therapy. The safety profile of lanreotide autogel 
was similar to that reported in earlier studies in patients 
with functioning and nonfunctioning tumours [8, 16].
At the time of enrolment, lanreotide was approved 
for the symptomatic treatment of NETs only. In Polish 
clinical practice, the registered indication allowed for 
the regular dosing interval of 28 days for lanreotide 
autogel 120 mg to be extended to 42 or 56 days, depend-
ing on the degree of symptomatic relief obtained, in the 
treatment of symptomatic NETs [16]. From the patient’s 
perspective, medication administration modality and 
frequency are factors that influence therapeutic com-
pliance, particularly in active patients with numerous 
priorities in their life [17]. In 2015, based on the results 
of the CLARINET study [8], showing a beneficial effect 
of lanreotide in reducing the risk of disease progression 
or death, lanreotide autogel 120 mg every 28 days was 
approved for the antitumoral treatment of GEP-NETs. 
The extended dosing regimens observed in LanroNET 
remain indicated for the symptomatic treatment of 
NETs only.
Real-world costs of SSAs, considered as the first-line 
symptomatic treatment of NETs, can be influenced by 
how they are used in clinical practice. The LanroNET 
study allowed prospective two-year follow-up of lan-
reotide autogel 120 mg regimens used, and observation 
of regular clinical practice to assess the treatment costs 
and resource utilisation in a real-life setting. It allowed 
a good estimation of economic aspects of the medical 
care provided to patients with functional NETs in Poland. 
The mean cost of consumed resources per patient 
per year (excluding pharmaceuticals) was estimated 
at PLN 26,307/EUR 6030 and represented around 92% 
of the total cost (Table II). The relatively low cost of 
diagnostic procedures, contributing to less than 0.5% 
of the total mean cost, may indicate that monitoring of 
the disease by imaging examinations in real practice 
was not followed in line with guidelines that recom-
mend it every 6–12 months in NET [3]. A small number 
of patients underwent a minimum of one diagnostic 
imaging procedure (n = 15) during the study, resulting 
in the diagnostic procedures annualised base case cost 
(Table II) being a few times lower than the mean unit 
cost (Supplementary Table S1). Treatment follow-up 
was focused mainly on clinical examination (outpatient 
visits) and biochemical marker determination. 
Table III. Dosing regimen and cost of lanreotide autogel 120 mg 
Tabela III. Schemat dawkowania i koszt lanreotide autogel 120 mg
Study time points Dosing intervals, n (%) Time between 
injections
mean ± SD [days]
Annualised number 
of injections#
mean ± SD 
Average cost of treatment##
mean/patient/28 days [PLN/EUR]
4 weeks 6 weeks 8 weeks 31.68 ± 6.71 10.45 ± 2.56 4216.30/966.48
Baseline (n = 54) 45 (83.3) 8 (14.8) 1 (1.9)
End of observation–24 
months follow-up (n = 26)
19 (73.1) 7 (30.3)
#four patients stayed only one day in the study, thus were not included into analysis. Five patients switched from lanreotide autogel 120mg to another NET treatment
##common payer and patient perspective. Calculated according to price from the reference [10]
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The calculated annualised cost of therapy with 
lanreotide autogel 120 mg per 28-day period (all dosing 
regimens) was PLN 4212.50/EUR 965.61 and PLN 3.80/ 
/EUR 0.87 from the public payer and patient perspec-
tive, respectively. This cost was lower than the cost 
for calculated standard 28-day dosing regimen (PLN 
4766.19/EUR 1092.53 and PLN 4.27/EUR 0.99, respec-
tively), which suggests that the lanreotide autogel EDI 
is economically preferable in cases when symptom 
control can be achieved and maintained. 
Today, use of lanreotide autogel 120 mg goes beyond 
symptomatic treatment of NETs. It should be noted that 
the antiproliferative effect of lanreotide is supported 
under the standard 28-day dosing regimen [8]. 
Pharmacoeconomic data comparing lanreotide auto-
gel and octreotide LAR in GEP-NETs have been reported 
from an analysis of the PHARMO Record Linkage Sys-
tem in the Netherlands. On average, the patient cost was 
7% less with lanreotide autogel than with octreotide LAR 
using a cost minimalisation model. The driver of cost 
savings was the longer injection interval with lanreo-
tide autogel. Mean injection intervals were 27 days for 
octreotide LAR and 31 days for lanreotide autogel [18]. 
Mean injection intervals observed in the Netherlands 
[18] and in the LanroNET study were similar. 
The LanroNET study focused on resources, costs, 
and practical aspects of lanreotide autogel 120 mg 
utilisation. By its design and non-interventional na-
ture, information about clinical outcomes of patients 
is limited. Many assessments were performed at the 
baseline visit (e.g. tumour proliferation), and in most 
cases were not assessed afterwards. Collected data 
concerned patients with symptomatic NETs receiving 
lanreotide autogel 120 mg for treatment of disease 
symptoms and should not be extended to the current 
broad use of the drug, which is the treatment of NETs 
through its antiproliferative activity. 
Conclusions
The LanroNET study is the first two-year observational 
study of patients with symptomatic NETs in Poland. It 
is also the first study evaluating such a long period of 
treatment with lanreotide autogel 120 mg in this patient 
population. The mean time between injections was 
longer than 28 days, reflecting the use of EDI in some 
patients and supporting the potential for lanreotide 
autogel 120 mg to reduce treatment burden and costs 
while treating the symptoms of NETs. 
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